Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus (itching), particularly for patients with chronic kidney disease undergoing hemodialysis.

Cara Therapeutics

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Devon Park BioVentures

Connecticut Innovations

Alta Partners

Ascent Biomedical Ventures

MVM Life Science Partners

Mitsubishi Corporation

Rho Capital Partners

Scottish Widows Investment Partnership

June 3rd is National Itch Day! At Cara Therapeutics, we understand that #pruritus is more than just an #itch for the millions of people who suffer from the burdensome condition. Chronic pruritus can be all-consuming and have a significant impact on overall well-being.

To learn how we’re working to transform the way pruritus is treated, visit www.CaraTherapeutics.com. #NationalItchDay

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 
https://lnkd.in/eaUj8FW8

Cara Therapeutics Reports First Quarter 2024 Financial Results https://lnkd.in/ehp6ZXKw

Today we honor the women and men who lost their lives while serving our nation. We will always remember their sacrifices for our freedom.

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 https://lnkd.in/eGKrm2U8

Our Cara Culture Club recently sponsored a school supply drive for SPEF - Stamford Public Education Foundation and gathered donations for K.T. Murphy Elementary School. We wish all the students and teachers a healthy and productive school year! #Stamford #CaraCares

Domain Not Resolving

HSTS

DNSSEC

U.S. Server Location

reCAPTCHA v2

Microsoft

Gravity Forms

Mobile Optimized

New Relic

Drupal

President and CEO

Chris Posner

President &CEO

Derek Chalmers

Chief Strategy Officer & Head of Investor Relations

Iris Francesconi

Chief Medical Officer

Joana Goncalves

Josef Schoell

Co-Founder & Chief Scientific Officer

Natasha Arora

Co-Founder & CEO

Nigam Arora

Board Member

Susan Shiff

Chief Financial Officer

Tom Reilly

Sr Vice President Regulatory Affairs and Quality Assurance

Beth Weinberg

Geoffrey W. Smith

Christopher Posner

Kevin Crowley

Christopher Moller

President & Chief Executive Officer

Harrison Bains

Director

Paul Beckett

Senior CMC Project Manager

Jeffrey Ives

Michael E. Lewis

Co-founder, Chief Scientific Advisor

Ryan Maynard

Frederique Menzaghi

Chief Scientific Officer, Senior VP Research & Development

Northeastern US Companies that Exited (Top 10K)

Northeastern US Female Founded Companies (Top 10K)

Therapeutics Public Companies With Fewer Than 1000 Employees

New England Companies With More Than 50 Employees (Top 10K)

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

HealthCare Royalty Partners

Post-IPO Debt - Cara Therapeutics

Post-IPO Equity - Cara Therapeutics

Rho Ventures

Series D - Cara Therapeutics

Series C - Cara Therapeutics

Series B - Cara Therapeutics

Shelton

Connecticut

United States

North America

North American Morning Briefing : Nasdaq Futures -2-

Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91%

In-Depth Analysis Of The Global Medical Marijuana Market: Key Drivers, Trends, Growth Opportunities, And Forecast 2033

Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company

Cara Therapeutics Announces Exploration of Strategic Alternatives

Cara Therapeutics seeks strategic options with Piper Sandler

Cara Therapeutics discontinues neurological condition study as drug fails

Cara Therapeutics to Cut 70% of Workforce

Cara Therapeutics announces 70% reduction in workforce (NASDAQ:CARA)

An FDA-approved therapy for treating moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Research and development efforts focused on treating pruritus in Notalgia Paresthetica, a chronic sensory neuropathy affecting the upper back.

El Salvador

Philippines

Asia

India

Germany

Europe

HTML5

Lightbox

Vimeo

Apache Server

Modernizr

DigiCert

Adobe Fonts

Google Compute Engine

Microsoft Outlook

Google Analytics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

news impact assignment basic	general
public peers	general	Jul 17, 2024 9:45 PM	2888bcc1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	77411843
crunchbase profile	general	Nov 22, 2024 1:42 PM	27773403
li profile	general	Jul 17, 2024 9:45 PM	45c99a1d
translate crunchbase fundingrounds	general	Nov 22, 2024 3:50 PM	651863e5
peers	general	Jul 17, 2024 9:45 PM	8972db24
news basic	general	Jul 17, 2024 9:45 PM	a2317fb6
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CARATHERAPEUTICS

Cara Therapeutics

Last Close

0.31

22/11 21:00

Market Cap

15.64M

Beta: -

Volume Today

508.47K

Avg: -